Mechanisms underlying the QT interval-prolonging - Effects of sevoflurane and its interactions with other QT-prolonging drugs

被引:44
|
作者
Kang, JS [1 ]
Reynolds, WP [1 ]
Chen, XL [1 ]
Ji, JZ [1 ]
Wang, HG [1 ]
Rampe, DE [1 ]
机构
[1] Sanofi Aventis, Dept Drug Safety Evaluat, US Safety Pharmacol, Bridgewater, NJ 08807 USA
关键词
D O I
10.1097/00000542-200605000-00018
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: Sevoflurane prolongs ventricular repolarization in patients, but the mechanisms are not fully characterized. The effects of sevoflurane on many cloned human cardiac ion channels have not been studied, and the interactions between sevoflurane and other drugs that prolong cardiac repolarization have not been detailed. Methods: The effects of sevoflurane on action potentials and L-type Ca2+ channels in guinea pig myocytes were examined. Sevofluarane's effects on cloned human cardiac K+ channels and the cloned human cardiac Na+ channel were studied. The consequences of combining sevoflurane and the class III antiarrhythmic drugs sotalol or dofetilide on action potential duration were also examined. Results: Sevoflurane produced an increase in action potential duration at concentrations of 0.3-1 m(M). Contrary to most drugs that delay ventricular repolarization, sevoflurane was without effect on the human ether-a-go-go-related gene cardiac potassium channel but instead produced a reduction in KvLQT1/minK K+ channel currents and inhibited the Kv4.3 K+ channel by speeding its apparent rate of inactivation. Sevoflurane had little effect on Na+ and Ca2+ channel currents at concentrations of 1 mm or less. When the authors coadministered sevoflurane with sotalol or dofetilide, synergistic effects on repolarization were observed, resulting in large increases in action potential duration (up to 66%). Conclusion: Prolonged ventricular repolarization observed with administration of sevoflurane results from inhibition of KvLQT1/minK and Kv4.3 cardiac K+ channels. Combining sevoflurane with class III antiarrhythmic drugs results in supra-additive effects on action potential duration. The results indicate that sevoflurane, when administered with this class of drug, could result in excessive delays in ventricular repolarization. The results suggest the need for further clinical studies.
引用
收藏
页码:1015 / 1022
页数:8
相关论文
共 50 条
  • [41] Electrophysiological, anatomical and histological remodeling of the heart to AV block enhances susceptibility to arrhythmogenic effects of QT-prolonging drugs
    Sugiyama, A
    Ishida, Y
    Satoh, Y
    Aoki, S
    Hori, M
    Akie, Y
    Kobayashi, Y
    Hashimoto, K
    JAPANESE JOURNAL OF PHARMACOLOGY, 2002, 88 (03): : 341 - 350
  • [42] Development in Prescriptions of Contraindicated and Potentially Harmful QT Interval-Prolonging Drugs in a Large Geriatric Inpatient Cohort From 2011 to 2021
    Then, Melanie, I
    Tuemena, Thomas
    Sledziewska, Anna
    Gassmann, Karl-Guenter
    Maas, Renke
    Fromm, Martin F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 (02) : 435 - 445
  • [43] Prevalence of QT-Prolonging Drug-Drug Interactions in Psychiatry: A Systematic Review and Meta Analysis
    Ramasubbu, Saravana Kumar
    Mishra, Archana
    Mandal, Soumitra
    JOURNAL OF PHARMACY PRACTICE, 2024, 37 (01) : 162 - 168
  • [44] An Issue Waiting to be Clarified: Effects of the QT Prolonging Drugs on Tp-e Interval Reply
    Claudio, Bruno de Queiroz
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2015, 104 (06) : 508 - 508
  • [45] COMPUTER-ASSISTED INTERVENTIONS TO IMPROVE QTC DOCUMENTATION IN PATIENTS RECEIVING QT-PROLONGING DRUGS
    Sandau, Kristin E.
    Sendelbach, Sue
    Fletcher, Linda
    Frederickson, Joel
    Drew, Barbara J.
    Funk, Marjorie
    AMERICAN JOURNAL OF CRITICAL CARE, 2015, 24 (02) : E6 - E14
  • [46] Serious ventricular arrhythmias among users of cisapride and other QT-prolonging agents in the United States
    Enger, C
    Cali, C
    Walker, AM
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2002, 11 (06) : 477 - 486
  • [47] Detection and Characterization of Pharmacogenomic Effects in Nonrandomized Studies - A Simulation Study of QT-Prolonging Drug-Gene Interactions
    Der, Jane
    Avery, Christy L.
    Whitsel, Eric A.
    Sturmer, Til
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 : S7 - S8
  • [48] QT-prolonging effects of monoclonal antibody drugs in humans: a systematic review of two literature and a public adverse event database
    Jackson, Torquil
    Kondic, Jelena
    Seebeck, Joerg
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2015, 53 (09) : 705 - 711
  • [49] Torsadogenic action of QT-prolonging drugs, astemizole and haloperidol, assessed by the canine chronic atrioventricular block model
    Sugiyama, A
    Satoh, Y
    Wada, K
    Nomura, H
    Nakamura, Y
    Hashimoto, K
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2004, 94 : 151P - 151P
  • [50] RISK OF VENTRICULAR TACHYCARDIA AND SUDDEN CARDIAC ARREST ASSOCIATED WITH QT INTERVAL-PROLONGING DRUGS IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION
    Huang, Chien-Yu
    Overholser, Brian
    Sowinski, Kevin
    Jaynes, Heather A.
    Kovacs, Richard J.
    Tisdale, James Edward
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 134 - 134